Compare SDOT & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SDOT | REVB |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 5.1M |
| IPO Year | 2019 | N/A |
| Metric | SDOT | REVB |
|---|---|---|
| Price | $2.07 | $1.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.6K | ★ 213.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 490.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,929,137.00 | N/A |
| Revenue This Year | $12.76 | N/A |
| Revenue Next Year | $5.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 60.08 | N/A |
| 52 Week Low | $0.72 | $0.47 |
| 52 Week High | $13.02 | $3.80 |
| Indicator | SDOT | REVB |
|---|---|---|
| Relative Strength Index (RSI) | 36.00 | 44.07 |
| Support Level | $1.18 | $0.77 |
| Resistance Level | $2.40 | $1.38 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 7.06 | 0.00 |
Sadot Group Inc operates in the food supply chain sector, connecting producers and consumers across the globe, delivering agri-commodities from producing geographies such as the Americas, Africa, and the Black Sea to consumer markets in Southeast Asia, China and the Middle East/North Africa (MENA) region. Its reportable segment includes Sadot food service and Sadot agri-foods. The key revenue is coming from the Sadot agri-foods segment which engaged in farming, commodity trading, and shipping of food and feed.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).